Dustin Dinning, DO
Rheumatology · Coeur D Alene, IDNPI 1578774022
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $269,512 of the $311,324 with a category attached, or 86.6%. 30 manufacturers reported payments, led by Amgen at 46.1% of the total. Reporting peaked in 2022 at $76,967 and has fallen 74.4% since, to $19,739 in 2025. Among rheumatology clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 718 payments — averaging $433.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$143K
- AbbVie$111K
- Lilly USA, LLC$46K
- Novartis$8K
- E.r. Squibb & Sons, L.L.C.$1K
- AstraZeneca$513
- plus $2K from 24 others
What the payments were for
- Consulting fees$6000%
- Speaking & faculty fees$269,51287%
- Travel & lodging$28,9849%
- Food & beverage$12,1494%
- Education$800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 302 | $143,373 |
| AbbVie | 206 | $110,628 |
| Lilly USA, LLC | 59 | $45,866 |
| Novartis | 34 | $8,296 |
| E.r. Squibb & Sons, L.L.C. | 14 | $1,010 |
| AstraZeneca(2 entities) | 22 | $513 |
| UCB, Inc. | 19 | $362 |
| Johnson & Johnson | 10 | $251 |
| GSK | 13 | $230 |
| Fresenius Kabi USA, LLC | 6 | $123 |
| Pfizer | 6 | $107 |
| ANI Pharmaceuticals, Inc. | 3 | $56 |
| Merck | 2 | $48 |
| Organon | 2 | $47 |
| Regeneron Healthcare Solutions, Inc. | 2 | $47 |
| Bayer | 2 | $43 |
| Mallinckrodt Hospital Products Inc. | 2 | $39 |
| Mallinckrodt Enterprises LLC | 2 | $36 |
| Aurinia Pharma U.S., Inc. | 1 | $28 |
| Sobi, Inc | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $24 |
| Tersera Therapeutics LLC | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Accord Healthcare, Inc. | 1 | $21 |
| Radius Health, Inc. | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Pacira Therapeutics, Inc. | 1 | $16 |
| Spectrum Pharmaceuticals Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$311,324 in reported general payments places this provider in the 95th percentile of 28 rheumatology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 167 | $1,308,257 |
| Humira(Cf) PenAdalimumab | 132 | $1,192,697 |
| RinvoqUpadacitinib | 104 | $911,899 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 47 | $351,807 |
| Humira(Cf)Adalimumab | 21 | $310,513 |
| Xeljanz XrTofacitinib Citrate | 38 | $290,825 |
| Orencia ClickjectAbatacept | 37 | $275,577 |
| EnbrelEtanercept | 24 | $232,652 |
| OtezlaApremilast | 42 | $211,517 |
| Cosentyx Unoready PenSecukinumab | 15 | $172,462 |
| Humira PenAdalimumab | 12 | $163,481 |
| Enbrel MiniEtanercept | 16 | $115,176 |
| KevzaraSarilumab | 21 | $94,135 |
| Cimzia (2 Pack)Certolizumab Pegol | 11 | $90,440 |
| Hydroxychloroquine Sulfate | 755 | $38,227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $110,628 | $1,222,413125 claims |
| AmgenEnbrel, Otezla | $143,373 | $444,16966 claims |
| UCB, Inc.Cimzia (2 Pack) | $362 | $90,44011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 28 rheumatology providers in Idaho.
Other rheumatology in Coeur D Alene
- Craig WiesenhutterCoeur D Alene$7K
- Linda SakaiCoeur D Alene$3K
- Philip MeadowCoeur D Alene$2K
- Sheena HenryCoeur D Alene$2K
- William KnibbeBoise$164K
- Craig ScovilleIdaho Falls$26K
- Christopher GibsonAshton$18K
- James LovelessBoise$12K
- Peggy Ann RuppBoise$11K
- Sean McMillanTwin Falls$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.